iX Biopharma Ltd. (SG:42C) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
iX Biopharma Ltd. reports promising results from their SEISMIC-CBD study, indicating that their novel CBD sublingual wafer, designed with their proprietary WaferiX technology, is safe and tolerable for kidney failure patients, showing potential to improve multiple debilitating symptoms. The study, a significant first in this patient group, also found meaningful improvements in sleep quality, restless legs syndrome, anorexia, pain, and anxiety. Despite some reported mild adverse effects, the majority of participants experienced symptom relief and some continued using the wafers beyond the study.
For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.